Early Discontinuation of P2Y12 Antagonists and Adverse Clinical Events Post–Percutaneous Coronary Intervention: A Hospital and Primary Care Linked Cohort by Daniel, Harris et al.
Early Discontinuation of P2Y12 Antagonists and Adverse Clinical
Events Post–Percutaneous Coronary Intervention: A Hospital and
Primary Care Linked Cohort
Daniel E. Harris, MSc; Arron Lacey, PhD; Ashley Akbari, MSc; Daniel R. Obaid, PhD; Dave A. Smith, MD; Geraint H. Jenkins, MA;
James P. Barry, MA; Mike B. Gravenor, DPhil; Julian P. Halcox, MD
Background-—Early discontinuation of P2Y12 antagonists post–percutaneous coronary intervention may increase risk of stent
thrombosis or nonstent recurrent myocardial infarction. Our aims were to (1) analyze the early discontinuation rate of P2Y12
antagonists post–percutaneous coronary intervention, (2) explore factors associated with early discontinuation, and (3) analyze the
risk of major adverse cardiovascular events (death, acute coronary syndrome, revascularization, or stroke) associated with
discontinuation from a prespeciﬁed prescribing instruction of 1 year.
Method and Results-—We studied 2090 patients (2011–2015) who were recommended for clopidogrel for 12 months (+aspirin)
post–percutaneous coronary intervention within a retrospective observational population cohort. Relationships between
clopidogrel discontinuation and major adverse cardiac events were evaluated over 18-month follow-up. Discontinuation of
clopidogrel in the ﬁrst 4 quarters was low at 1.1%, 2.6%, 3.7%, and 6.1%, respectively. Previous revascularization, previous ischemic
stroke, and age >80 years were independent predictors of early discontinuation. In a time-dependent multiple regression model,
clopidogrel discontinuation and bleeding (hazard ratio=1.82 [1.01–3.30] and hazard ratio=5.30 [3.14–8.94], respectively) were
independent predictors of major adverse cardiac events as were age <49 and ≥70 years (versus those aged 50–59 years),
hypertension, chronic kidney disease stage 4+, previous revascularization, ischemic stroke, and thromboembolism. Furthermore, in
those with both bleeding and clopidogrel discontinuation, hazard ratio for major adverse cardiac events was 9.34 (3.39–25.70).
Conclusions-—Discontinuation of clopidogrel is low in the ﬁrst year post–percutaneous coronary intervention, where a clear
discharge instruction to treat for 1 year is provided. Whereas this is reassuring from the population level, at an individual level
discontinuation earlier than the intended duration is associated with an increased rate of adverse events, most notably in those
with both bleeding and discontinuation. ( J Am Heart Assoc. 2019;8:e012812. DOI: 10.1161/JAHA.119.012812.)
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P oor medication adherence is often associated withadverse patient events across multiple disease out-
comes. This is of particular concern in the setting of modern
cardiac intervention with stent implantation for acute
coronary syndromes (ACS), where discontinuation of anti-
platelet therapy risks both stent stenosis and non-stent-
related myocardial infarction (MI). As such, the use of dual
antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, in
patients undergoing coronary revascularization is an estab-
lished treatment strategy in the prevention of short- and long-
term thrombotic complications.1–3
Current guidelines recommend a minimum of 12 months
of DAPT for patients presenting with ACS undergoing coronary
percutaneous coronary intervention (PCI) with stent implan-
tation, reduced to at least 6 months in the presence of risk
factors for bleeding.4,5 In patients with stable coronary artery
disease, a minimum of 6 months is recommended following
drug eluting stents implantation and at least 1 month
following a bare metal stent or in those with a high risk of
bleeding. The presence of comorbidities, such as atrial
ﬁbrillation (AF), may necessitate the need for concomitant
anticoagulation and therefore shorter durations of DAPT may
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be warranted. Likewise, the need to undergo surgery in the
future may also mandate shorter durations of DAPT.
A number of observational studies have shown that an
increase in major adverse cardiac events is associated with a
delay in access to prescriptions for P2Y12 inhibitors following
coronary PCI6,7 or premature discontinuation following an MI
or stent implantation.8–13 Rates of discontinuation vary
between studies, with some reporting 13% discontinuation
within 30 days10 and others up to 40% to 50% within
1 year.8,9 However, these studies have not identiﬁed the
intended duration of therapy postdischarge or taken account
of comorbidities that may warrant shorter durations of DAPT.
Furthermore, the study populations were predominantly
medically treated ACS8,14 or, in the case of the PARIS
(Patterns of Non-Adherence to Antiplatelet Regimens in
Stented Patients) registry, predominantly stable angina
patients undergoing PCI.15
Our objectives were to (1) analyze the rate of early
discontinuation of clopidogrel following discharge from hos-
pital in a post-PCI population where the duration of DAPT was
speciﬁed for 1 year, (2) explore potential factors associated
with discontinuation in prescribing, and (3) analyze the risk of
death and major cardiovascular events associated with
discontinuation.
Methods
We undertook a retrospective observational cohort study
using linked anonymized healthcare data from the SAIL
(Secure Anonymised Information Linkage) Databank16,17 for
patients undergoing PCI at a tertiary cardiac center in
Wales. The study population was identiﬁed from the cardiac
intervention database and included patients who were
discharged from the hospital (between January 2011 and
November 2015) following PCI for either stable or acute
coronary artery disease. Follow-up was for 18 months.
Patients who underwent coronary artery bypass grafting
(CABG) during the index admission or had a previous or
contemporary diagnosis of AF were excluded from the
study.
This study makes use of anonymized patient data;
therefore, informed consent was not required. Approval for
the study was granted by the SAIL IGRP (Information
Governance Review Panel). All data can be made available
to researchers by standard SAIL IGRP protocols.
Approval for data access and processing was granted by
the SAIL independent Information Governance Review
Panel (IGRP) project number: 0441. Permission was granted
from the respective health board data custodians of the
Cardiac intervention dataset and the hospital discharge
prescribing data sets.
Data Sets and Linkage
The cardiac intervention data set contains procedural, clinical,
and demographic data on patients undergoing PCI. Informa-
tion on the prescribing of antithrombotic therapy was
obtained from the hospital discharge summaries. These data
sets were linked to the WLGP (Welsh Longitudinal General
Practice) data set to record the continuity of antithrombotic
therapy and presence of comorbidities, risk factors, and
demographics.18 Date of death, where relevant, was identiﬁed
form the ADDE (Annual District Death Extract)19 containing
mortality records from the ONS (Ofﬁce of National Statistics),
and deprivation quintile was assigned using the WIMD (Welsh
Index of Multiple Deprivation), an area-based deprivation
measure.20
For each patient hospitalized in Wales, the PEDW (Patient
Episode Database for Wales) records the admission and
discharge dates, diagnoses, and operational procedures and
demographic data. Date of death is also recorded when the
patient dies within the hospital. These records are completed
at ﬁnished consultant episode. Within each ﬁnished consul-
tant episode, 1 primary and ≥1 secondary diagnosis, using the
International Classiﬁcation of Disease, Tenth Revision (ICD-10),
are recorded. Operational and procedural codes are also
applied for each ﬁnished consultant episode following the
OPCS-4 (Ofﬁce of Population Censuses and Surveys Classi-
ﬁcation of Interventions and Procedures version 4). The PEDW
was used to describe cardiac revascularization (either PCI or
CABG) and major bleeding events preceding the index
Clinical Perspective
What Is New?
• In this real-world study following patients discharged post–
percutaneous coronary intervention where the duration of
dual antiplatelet therapy was known, discontinuation of
P2Y12 antagonist therapy was low and much lower than
reported in other studies.
• Despite the low discontinuation rate, it was an important
predictor of major adverse outcomes in this population,
especially in those with concomitant bleeding.
What Are the Clinical Implications?
• Discontinuation of P2Y12 antagonist therapy earlier than
intended is associated with an increased rate of adverse
events, highlighting the importance of processes optimizing
concordance with evidence-based preventative therapy
post–percutaneous coronary intervention.
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admission (see Table S1 for ICD-10 codes used to identify
bleeding events). Major bleeding events included gastroin-
testinal bleeds, intracranial bleeds, urinary tract bleeds, and
airway bleeds.
Both the PEDW and WLGP data sets were searched for
past history or contemporary diagnosis of vascular disease
(peripheral artery disease or aortic plaque), AF/ﬂutter, MI,
Ischemic stroke, thromboembolism, and heart failure.
Index Event Data
For each patient, the ﬁrst entry in the cardiac intervention
database occurring during the study period was identiﬁed as
the index intervention. Dates of admission and discharge were
identiﬁed either side of the index intervention using the PEDW
data set. Prescribing data corresponding to the index
intervention were extracted from the electronic discharge
summaries. Where an electronic discharge summary was not
available, paper copies of the discharge summary, where
available, were searched and the prescribing data were
recorded.
P2Y12 Antagonist Prescribing and
Discontinuation
Prescribing of P2Y12 antagonists postdischarge was recorded
within consecutive 3-month periods following the date of
discharge from hospital. Discontinuation was deemed to have
occurred when there was a 3-month period without a P2Y12
antagonist prescription before the intended date of treatment
cessation. The precise time to discontinuation is unknown,
but was approximated as the center point within the ﬁrst 3-
month period where no P2Y12 antagonist had been pre-
scribed, that is, 46 days for the ﬁrst 3-month period;
137 days for the second 3-month period; and 228, 319,
411, and 501 days for the third to sixth three-month periods,
respectively.
Statistical Analyses
Baseline variables and patient characteristics, including
demographics, lifestyle behaviors, and medical history, are
presented as percentages and means with SDs. Differences
between those prescribed P2Y12 therapy for 1 year and all
other regimes were compared using the v2 test for
categorical variables and the 2-sample t test for continuous
variables. A Cox proportional hazards model was used to
determine the baseline characteristics associated with “time
to discontinuation” from the prescribing instruction at the
point of discharge from the hospital. Bleeding subsequent to
PCI, occurring during the period of intended prescription
duration, was included as a time-dependent covariate.
Hazard ratios (HRs) and 95% CIs were calculated for the
respective clinical variables. In analyzing time to discontin-
uation, death during the follow-up was treated as a
censoring event, and hence we assumed that the time to
death (or other loss to follow-up) was not related to the
time-to-attrition distribution.
The primary clinical end point was a combination of death
of any cause, subsequent readmission to hospital for an MI,
unstable angina, acute ischemic heart disease, ischemic
stroke or transient ischemic attack, or readmission after
30 days from the index discharge date for either CABG or
recurrent coronary PCI (see Tables S2 and S3 for ICD-10 and
OPCS codes used to establish these end points). A Cox
proportional hazards model was used to determine charac-
teristics of the cohort associated with this adverse composite
outcome; speciﬁcally the effect of discontinuation was
modeled as a time-dependent covariate. In estimating the
effect of discontinuation, we attempted to control for
expected risk factors by including the key baseline charac-
teristics in the Cox model. In addition, we had to control for
effects of bleeding, again as a time-dependent covariate. We
created a covariate with 4 levels representing the overall time-
dependent classiﬁcation: no discontinuation and no bleed,
discontinuation occurred but no bleed, bleed occurred but no
discontinuation, and, ﬁnally, both events have occurred. For
those patients with an adverse outcome, only discontinuation
and/or bleeding events occurring before the end point were
included in the analysis. All models were run in SPSS software
(version 22.0; SPSS, Inc., Chicago, IL). Variables were initially
considered separately in univariable analyses; the ﬁnal
multivariable Cox model was selected by minimizing the
Akaike information criterion (with a comparison to model
selection using Bayesian information criteria).
Results
Study Population
Of the 5532 patients undergoing PCI during the study period,
3066 (55.4%) were discharged and had a complete linked
healthcare data set available (Figure 1). A further 397 (7.2%)
were excluded who had AF or underwent a CABG procedure
during the index admission. Of the ﬁnal 2770 patients
meeting the inclusion criteria, 2090 (75.5%) were prescribed
clopidogrel for 1 year (plus aspirin 75 mg once-daily for life).
Of this cohort, mean age was 63.2 years, 73.5% were male,
and 86.5% underwent PCI for an ACS (Table 1). In comparison
with those prescribed any other regimen on discharges, these
patients had a lower mean age; lower rate of previous
diagnoses for ischemic heart disease; MI, previous coronary
revascularization, heart failure, or dyslipidemia; and were less
likely to have been prescribed in the year preceding the index
event either aspirin, P2Y12 inhibitors, or statins (further
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comparisons between those included and those excluded
[with or without discharge prescribing data available] are
contained in Table S4).
Clopidogrel Discontinuation
Rate of discontinuation during the periods 0 to 3, 3 to 6, 6 to
9, and 9 to 12 months postdischarge was 1.1%, 2.6%, 3.7%,
and 6.1%, respectively (Figure 2). Between 12 and
15 months, 47% had discontinued clopidogrel and 76.2% by
15 to 18 months.
Factors associated with clopidogrel discontinuation during
the ﬁrst 12 months included: increasing age, hypertension,
ischemic heart disease, previous MI, previous coronary
revascularization, ischemic stroke, heart failure, vascular
disease, previous bleeding events, and bleeding during the
follow-up period (Figure 3). After adjusting for all baseline
characteristics, previous revascularization, previous ischemic
stroke, and age groups ≥80 years were independently
associated with discontinuation (Table 2).
Death and Major Cardiovascular Events
Incidence of death or major cardiovascular events in those
who had no discontinuation or bleeding events postdischarge
was 9.5 per 100 person-years (95% CI, 8.39–10.74); in
patients who had discontinued clopidogrel but had no
bleeding events, the incidence was 15.2 (95% CI, 6.72–
24.24); in patients who had a bleeding event but no
discontinuation, it was 41.9 (95% CI, 21.38–60.10); and in
patients who had both bleeding and discontinuation, it was
64.6 per 100 person-years (95% CI, 1.29–127.96).
Patient characteristics associated with death or major
cardiovascular events included: age ≤49 or ≥60 compared
with those aged 50 to 59, hypertension, previous MI, previous
coronary revascularization, ischemic stroke, heart failure,
vascular disease, thromboembolism, diabetes mellitus,
chronic kidney disease, chronic liver disease, clopidogrel
discontinuation, and bleeding during follow-up (Figure 4).
Characteristics independently associated with death
or major cardiovascular events in a multivariable Cox
Figure 1. Study population cohort selection. AF indicates atrial ﬁbrillation; CABG, coronary artery bypass graft; PCIs, percutaneous coronary
interventions; WLGP, Welsh Longitudinal General Practice.
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proportional hazards model included age <49 and ≥70 years
compared with those aged 50 to 59; previous coronary
revascularization; and a history of thromboembolism, chronic
kidney disease stage 4 or 5, and ischemic stroke (Table 3).
After adjustment for these factors, the time-dependent effects
of discontinuation and bleeding were signiﬁcantly associated
with death or major cardiovascular events. For discontinua-
tion alone, there was an estimated HR of 1.82 (95% CI, 1.01–
3.30) compared with patients with no discontinuation and no
bleeding events. Similarly, the occurrence of bleeding alone in
those without discontinuation was associated with an
increased risk of death or major cardiovascular events
(HR=5.30; 95% CI, 3.14–8.94). Notably, the combined effect
of having both discontinuation and bleeding was associated
with the greatest likelihood of adverse events (HR=9.34; 95%
CI, 3.39–25.70).
Model selection was also explored using Bayesian infor-
mation criteria. This resulted in selection of fewer patient
characteristics; however, the effects of bleeding and clopido-
grel discontinuation were retained in the ﬁnal model as
statistically signiﬁcant.
For completeness, the characteristics associated with the
individual outcomes of MI, stroke, revascularization, and
death are presented in Tables S5 and S6. Assessment of risk
factors associated with bleeding was not a primary objective
of this study, but nonetheless an important consideration. In a
multivariable analysis, previous bleeding events (HR=2.82;
95% CI, 1.67–4.76), chronic kidney disease (HR=6.15; 95% CI,
2.22–17.08), and chronic liver disease (HR=3.62; 95% CI,
1.14–11.51) were independently associated with bleeding
events during follow-up (Table S7). These variables were not
independently associated with risk of clopidogrel discontinua-
tion.
Discussion
This is the ﬁrst real-world outcome study examining the rate
of clopidogrel discontinuation following PCI where the
intended prescribing duration of DAPT is known. Notably,
discontinuation of P2Y12 inhibitor therapy is low in this
population, where a speciﬁed prescribing instruction to
continue for 12 months is provided, in contrast to other
studies where the prescribing duration was not known.
Furthermore, despite the low discontinuation rate, discontin-
uation was still identiﬁed as an important predictor of adverse
outcomes in this population, especially in those with
concomitant bleeding.
The observed rate of discontinuation is in marked contrast
with ﬁndings from previous studies, where it had been
suggested that up to a half of patients post-MI discontinue
therapy within 12 months.8 We note that this was observed in
a historical ACS patient group who were predominantly
treated medically as opposed to receiving contemporary PCI
therapy. Nevertheless, our observed rate of discontinuation
was still lower than expected. There are a number of possible
Table 1. Demographics and Medical History of Patients by
Discharge Prescribing Intention of P2Y12 Inhibitors (N=2770)
Clopidogrel
for 1 year
Other
Regimens
P Valuen=2090 n=680
Percentage of total group 75.5% 24.5%
Mean age, y (SD) 63.2 (11.8) 66.6 (12.3) <0.001
Characteristic, n (%)
Male 1537 (73.5) 450 (66.2) 0.001
Obese 511 (24.4) 181 (26.6) 0.097
Smoker 784 (37.5) 237 (34.9) 0.579
Deprivation index 0.08
1 (most deprived) 337 (16.1) 129 (18.9)
2 411 (19.7) 129 (18.9)
3 489 (23.4) 166 (24.4)
4 415 (19.9) 106 (15.9)
5 (least deprived) 398 (19.0) 138 (20.2)
Unknown 40 (1.9) 12 (1.8)
Past medical history, n (%)
Hypertension 851 (40.7) 303 (44.6) 0.074
Ischemic heart disease 612 (29.3) 242 (35.6) 0.002
Myocardial infarction 351 (16.8) 144 (21.2) 0.01
Coronary
revascularization
203 (9.7) 98 (14.4) 0.001
Ischemic stroke 115 (5.5) 46 (6.8) 0.22
Heart failure 259 (12.4) 67 (9.9) <0.001
Peripheral vascular
disease
81 (3.9) 46 (6.8) 0.002
Thromboembolism 14 (0.7) 9 (1.3) 0.10
Diabetes mellitus 382 (18.3) 156 (23.0) 0.007
Chronic kidney
disease stage 4+
16 (0.8) 10 (1.5) 0.097
Chronic liver disease 24 (1.1) 7 (1.0) 0.80
Dyslipidemia 380 (18.2) 149 (21.9) 0.031
Dementia 9 (0.4) 4 (0.6) 0.60
Previous bleeding events 205 (9.8) 89 (13.1) 0.16
Medication prescribed within 1 y before admission, n (%)
Aspirin 711 (34.0) 282 (41.5) <0.001
P2Y12 antagonist 230 (11.0) 107 (15.8) 0.001
Statins 924 (44.2) 347 (51.0) 0.002
Clinical syndrome, n (%) 0.045
Acute coronary syndrome 1808 (86.5) 563 (82.8)
Stable coronary disease 282 (13.5) 117 (17.2)
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explanations for this difference, including greater contempo-
rary recognition of the importance of continued use of P2Y12
inhibitors post-PCI, improved communication of the prescrib-
ing intention from secondary to primary care, and, possibly,
the availability of free prescriptions to all patients in Wales.
However, addressing these questions was outside the scope
of this study.
Among those patients who discontinued clopidogrel
earlier than the initial intended period, the hazard of death
or major cardiovascular events was greater compared with
those who continued therapy, as expected and in keeping
with previous studies.8,21 Other independent predictors of
adverse outcomes included ischemic stroke and previous
revascularization; both likely markers of diffuse or severe
cardiovascular disease. However, both ischemic stroke and
previous revascularization were also predictors of discontin-
uation. Whether these contrasting ﬁndings are a conse-
quence of shared risk factors, such as aging, comorbidities,
or the index PCI, being a consequence of poor adherence to
medication is unknown.
Other independent predictors of discontinuation included
advanced age, which has previously been shown to be a
predictor of early discontinuation of clopidogrel post-MI.
Bleeding events measured as a time-dependent variable
were not an independent predictor of discontinuation,
contrasting with observations from a previous study.8 It is
possible that those patients with previous bleeding events
or at higher risk of bleeding may have been instructed for
a shorter course of DAPT at discharge and were therefore
not included in this analysis. The exclusion of patients
undergoing CABG and those with AF, both groups of which
are at higher risk of bleeding and subsequent discontinu-
ation of P2Y12 treatment, may explain this observation. We
found no association between deprivation quintiles and
clopidogrel discontinuation, nor deprivation quintiles and
major adverse outcomes in univariable analyses. Therefore,
deprivation index was not included in the ﬁnal multivariable
analyses.
In this study, we documented gastrointestinal bleeds,
intracranial bleeds, urinary tract bleeds, and airway bleeds in
order to be consistent with previous studies,22 but bleeding
events occurring in other organ systems may have had major
clinical outcomes and resulted in cessation of therapy.
However, the lack of an accepted standard for deﬁning
relevant bleeding events and deﬁning their severity in real-
world data sets is a recognized limitation for studies such as
these.
Bleeding events were also highly predictive of adverse
outcomes, as expected. Bleeding is a recognized adverse
consequence of antiplatelet therapy and is associated with a
greater incidence of death and ischemic events.1,3,23,24 We
found that the greatest risk of death or major cardiovascular
events occurred in those with both discontinuation and
bleeding events in our cohort. While it is not possible to
identify the speciﬁc cause of adverse outcomes in this group,
it is recognized that contributing factors to worse outcomes
include the triggering of prothrombotic and -inﬂammatory
responses following a bleed, combined with discontinuation of
Figure 2. Discontinuation of clopidogrel post-Percutaneous Coronary Intervention.
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antiplatelet therapy leading to a rebound increased risk of
ischemic events.
While discontinuation was reassuringly low in the ﬁrst
12 months, it is notable that continuation of prescribing
beyond 12 months was high with almost one-quarter (24%
[n=427]) of patients still receiving a prescription for clopido-
grel between 15 and 18 months after discharge from the
index event. Possible reasons for continuation of clopidogrel
include recurrent ischemic events; however, we noted that
only 22.5% (n=96) within this group had a documented
readmission for recurrent major cardiovascular events during
follow-up. It is possible that further clinical events occurred
that led to a decision to continue or change therapy, although
it is unlikely that this was the case for the majority of patients.
Given that prescriptions are provided free in Wales, there is no
ﬁnancial disincentive to stop treatment, which may explain
the relatively high numbers of patients continuing treatment
beyond the recommended period.
Figure 3. Characteristics associated with clopidogrel discontinuation within 1 year of discharge during follow up using univariable Cox
proportional hazards model. ACS indicates acute coronary disease; CAD, coronary artery disease; CKD, chronic kidney disease; HR, hazard ratio;
MI, myocardial infarction.
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Given that the data set only examined outcomes up to
18 months, there was insufﬁcient power to explore the
relationship between extended prescriptions beyond
12 months and the effect on either cardiovascular events or
bleeding attributable to relatively low numbers and short
exposure times.
Strengths and Limitations of this Study
We believe that this study further reﬁnes our understanding
of the impact of P2Y12 discontinuation on clinical outcomes.
By identifying the discharge prescribing intention, we have
avoided overestimation by excluding those with shorter
durations of DAPT. Thus, although our analysis only
evaluates 40% of the entire PCI population, we believe that
these patients are representative of the majority of the post-
PCI population who are recommended to receive 1 year of
DAPT, given that our analysis has excluded patients
requiring anticoagulation, those undergoing surgery, and
those without a complete linked data set. There were also
many clinical and demographic differences between those
directed to 1 year of clopidogrel and the remaining group
who had greater prevalence of risk factors for both
cardiovascular and bleeding events. By keeping those
higher-risk patients in the analyses, over-representation of
these important risk factors would likely have led to further
overestimation of the actual relationship between discontin-
uation and adverse cardiovascular events. Furthermore, the
exclusion of those with AF and/or undergoing CABG, who
are at higher risk of bleeding and subsequent discontinua-
tion of P2Y12 inhibitors, has likely further reduced the rate
of discontinuation and the effect of bleeding events leading
to discontinuation.
There are several limitations to this study. While we have
identiﬁed the prescribing intention from the hospital, we
were not able to identify the quantity of medication issued
from either hospital or primary care; therefore, we were
unable to calculate precisely when an individual’s prescrip-
tion would have ﬁnished if taken according to instruction. In
the WLGP data set, we noted that prescriptions were usually
issued every month, but occasionally repeated every
2 months. Within a 3-month period, if no prescription had
been issued, it was possible to assume that either a 1- or 2-
month supply made in the previous quarter had been
exhausted. Discontinuation was deemed to have occurred
when there was a 3-month period without a P2Y12
antagonist prescribed. Using this method, we were able to
detect periods where we had greater certainty that an
individual’s prescription was likely to have ﬁnished, but we
lacked the precision for identiﬁcation of shorter periods of
discontinuation.
As with any observational studies, we cannot determine
whether the association between clopidogrel discontinuation and
adverse outcomes was causal or may have been confounded by
the inﬂuence of unrecorded comorbidities, including unrecorded
bleeding events, the underutilization of other prognostically
relevant medicines, or new undocumented behaviors. The
prescribing and potential discontinuation from aspirin was not
accounted for in this study. In the UK, aspirin is widely available
without a prescription and is inexpensive; therefore, the assess-
ment of aspirin discontinuation from theWLGP data setmay have
led to classiﬁcations of periods of discontinuation when a patient
may have self-medicated.
It was not possible to identify the cause of discontinuation in
this study. While the recording of prescriptions issued from the
WLGP data set is robust, currently it is not possible to identify the
dispensing of those prescriptions. Access to prescription
dispensing records in addition to the prescribing records from
the WLGP data set would have improved the sensitivity of
capturing periods “off treatment” and the association between
nonadherence as well as discontinuation and adverse outcomes.
Furthermore, it is not possible to identify whether patients took
themedication as intended, as is the case inmost clinical studies.
Therefore, this study does not conﬁrm whether compliance with
medication and periods of discontinuation could be attributed to
either intentional or unintentional patient noncompliance or
intentional prescriber discontinuation. It is possible that patients
recorded as having discontinued clopidogrel received prescrip-
tions either privately or from outpatient hospital appointments,
although rare in Wales, neither of which would have been
captured in this study. However, this would likely further increase
the true difference in the effect of discontinuation on adverse
outcomes.
During the study period, international guidelines changed
to preferentially recommending the use of the more-potent
Table 2. Multivariable Cox Proportional Hazard Model of
Characteristics Associated With Clopidogrel Discontinuation*
Covariate
Hazard
Ratio
Lower
CI
Upper
CI P Value
Age, y
≤49 1.61 0.84 3.08
50 to 59 Reference 0.005
60 to 69 1.47 0.86 2.53
70 to 79 1.51 0.84 2.69
≥80 3.25 1.79 5.88
Previous
revascularization
2.09 1.32 3.33 0.002
Previous ischemic stroke 1.95 1.12 3.39 0.018
*The following variables were included in the mutually adjusted model: age; sex;
presenting clinical syndrome; hypertension; previous coronary revascularization;
previous bleeding events; ischemic stroke; heart failure; vascular disease;
thromboembolism; diabetes mellitus; chronic kidney disease stage 4+; chronic liver
disease, dyslipidemia; and dementia.
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P2Y12 antagonists such as ticagrelor or prasugrel. However,
attributable largely to ﬁnancial restrictions within the Welsh
health service, clopidogrel remained the mainstay of treat-
ment for ACS during this time. Although this article addresses
the use of clopidogrel post-PCI, we believe this article remains
of critical value given that it illustrates the importance of
knowing the schedule duration of any therapy before drawing
conclusions on the impact of early discontinuation. Although
not addressed in this study, one may expect the adverse
impact of poor concordance with newer, more-effective
therapies to be even greater.
Last, this observational study was conducted within a
health service that is both accessible and free at the point of
care, including the free provision of medication. This should
be born in mind when comparing the results of this study
with those systems where access to health care and
affordability may inﬂuence therapy and outcomes at a
population level.
Figure 4. Characteristics associated with major adverse outcomes calculated using univariable Cox proportional hazards model. ACS
indicates acute coronary disease; CAD, coronary artery disease; CKD, chronic kidney disease; HR, hazard ratio; MI, myocardial infarction.
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Conclusion
In conclusion, this study has demonstrated that identifying the
intended duration of P2Y12 antagonist therapy on discharge
following a PCI is essential for determination of the correct rate of
premature discontinuation in real-world outcome studies. The
rate of discontinuation was reassuringly low in this patient group
andmuch lower than anticipated in previous studies. While this is
reassuring from the population level, at an individual level,
discontinuation of P2Y12 antagonist therapy earlier than the
intended duration is associated with an increased rate of adverse
events. Our data emphasize the importance of improving
processes to ensure optimal concordance with evidence-based
preventative therapy post-PCI.
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Table S1. ICD-10 Codes for major bleeding events. 
MAJOR BLEEDING EVENTS 
Major bleeding events were classified as gastrointestinal bleeds, intracranial bleeds, urinary 
tract bleeds and airway bleeds resulting in admission to hospital. 
Bleeding event Code Description 
Intracranial hemorrhage I608 Other subarachnoid hemorrhage 
Intracranial hemorrhage I602 Subarachnoid hemorrhage from anterior 
communicating artery 
Intracranial hemorrhage I604 Subarachnoid hemorrhage from basilar artery 
Intracranial hemorrhage I600 Subarachnoid hemorrhage from carotid siphon and 
bifurcation 
Intracranial hemorrhage I607 Subarachnoid hemorrhage from intracranial artery 
unspecified 
Intracranial hemorrhage I601 Subarachnoid hemorrhage from middle cerebral artery 
Intracranial hemorrhage I606 Subarachnoid hemorrhage from other intracranial 
arteries 
Intracranial hemorrhage I603 Subarachnoid hemorrhage from posterior 
communicating artery 
Intracranial hemorrhage I605 Subarachnoid hemorrhage from vertebral artery 
Intracranial hemorrhage I609 Subarachnoid hemorrhage unspecified 
Intracranial hemorrhage I629 Intracranial hemorrhage (non-traumatic) unspecified 
Intracranial hemorrhage I613 Intracerebral hemorrhage in brain stem 
Intracranial hemorrhage I614 Intracerebral hemorrhage in cerebellum 
Intracranial hemorrhage I611 Intracerebral hemorrhage in hemisphere cortical 
Intracranial hemorrhage I610 Intracerebral hemorrhage in hemisphere subcortical 
Intracranial hemorrhage I612 Intracerebral hemorrhage in hemisphere unspecified 
Intracranial hemorrhage I615 Intracerebral hemorrhage intraventricular 
Intracranial hemorrhage I616 Intracerebral hemorrhage multiple localized 
Intracranial hemorrhage I619 Intracerebral hemorrhage unspecified 
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Intracranial hemorrhage I618 Other intracerebral hemorrhage 
Intracranial hemorrhage I691 Sequelae of intracerebral hemorrhage 
Intracranial hemorrhage I692 Sequelae of other non-traumatic intracranial 
hemorrhage 
Intracranial hemorrhage S064 Epidural hemorrhage 
Intracranial hemorrhage S065 Traumatic subdural hemorrhage 
Intracranial hemorrhage S066 Traumatic subarachnoid hemorrhage 
Gastrointestinal 
hemorrhage 
K250 Gastric ulcer acute with hemorrhage 
Gastrointestinal 
hemorrhage 
K254 Gastric ulcer chronic or unspecified with hemorrhage 
Gastrointestinal 
hemorrhage 
K260 Duodenal ulcer acute with hemorrhage 
Gastrointestinal 
hemorrhage 
K264 Duodenal ulcer chronic or unspecified with 
hemorrhage 
Gastrointestinal 
hemorrhage 
K270 Peptic ulcer acute with hemorrhage 
Gastrointestinal 
hemorrhage 
K280 Gastrojejunal ulcer acute with hemorrhage 
Gastrointestinal 
hemorrhage 
K920 Hematemesis 
Gastrointestinal 
hemorrhage 
K921 Melaena 
Gastrointestinal 
hemorrhage 
K922 Gastrointestinal hemorrhage unspecified 
Airway hemorrhage J942 Hemothorax 
Airway hemorrhage R042 Hemoptysis 
Airway hemorrhage R048 Hemorrhage from other sites in respiratory passages 
Urinary tract 
hemorrhage 
R31X Unspecified hematuria 
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Urinary tract 
hemorrhage 
N028 Recurrent and persistent hematuria  
Urinary tract 
hemorrhage 
N029 Recurrent and persistent hematuria unspecified 
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Table S2. ICD10 codes for major adverse outcomes. 
 
PRIMARY END POINT CODES 
The primary end point was death of any cause, subsequent readmission to hospital for an MI, 
unstable angina, acute ischemic heart disease, ischemic stroke or transient ischemic attack 
(TIA) or readmission after 30 days from the index discharge date for either CABG, or recurrent 
coronary PCI.  
 
Diagnosis Code Description of code 
MI I219 Acute myocardial infarction unspecified 
MI I214 Acute subendocardial myocardial infarction 
MI I210 Acute transmural myocardial infarction of anterior wall 
MI I211 Acute transmural myocardial infarction of inferior wall 
MI I212 Acute transmural myocardial infarction of other sites 
MI I213 Acute transmural myocardial infarction of unspecified site 
MI I220 Subsequent myocardial infarction of anterior wall 
MI I221 Subsequent myocardial infarction of inferior wall 
MI I228 Subsequent myocardial infarction of other sites 
Acute ischemic 
heart disease 
I249 Acute ischemic heart disease  
Unstable angina I200 Unstable angina 
Ischemic Stroke / 
TIA 
I661 Occlusion and stenosis of anterior cerebral artery 
Ischemic Stroke / 
TIA 
I663 Occlusion and stenosis of cerebellar arteries 
Ischemic Stroke / 
TIA 
I660 Occlusion and stenosis of middle cerebral artery 
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Ischemic Stroke / 
TIA 
I664 Occlusion and stenosis of multiple and bilateral cerebral arteries 
Ischemic Stroke / 
TIA 
I668 Occlusion and stenosis of other cerebral artery 
Ischemic Stroke / 
TIA 
I662 Occlusion and stenosis of posterior cerebral artery 
Ischemic Stroke / 
TIA 
I669 Occlusion and stenosis of unspecified cerebral artery 
Ischemic Stroke / 
TIA 
I64X Stroke not specified as hemorrhage or infarction 
Ischemic Stroke / 
TIA 
I651 Occlusion and stenosis of basilar artery 
Ischemic Stroke / 
TIA 
I652 Occlusion and stenosis of carotid artery 
Ischemic Stroke / 
TIA 
I653 Occlusion and stenosis of multiple and bilateral pre cerebral arts 
Ischemic Stroke / 
TIA 
I658 Occlusion and stenosis of other precerebral artery 
Ischemic Stroke / 
TIA 
I659 Occlusion and stenosis of unspecified precerebral artery 
Ischemic Stroke / 
TIA 
I650 Occlusion and stenosis of vertebral artery 
Ischemic Stroke / 
TIA 
G458 Other transient cerebral ischemic attacks and related syndrome 
Ischemic Stroke / 
TIA 
G459 Transient cerebral ischemic attack unspecified 
Ischemic Stroke / 
TIA 
I636 Cerebral infarct due cerebral venous thrombosis nonpyogenic 
Ischemic Stroke / 
TIA 
I632 Cerebral infarct due unspecifed occlusion or stenos precerebral 
arteries 
Ischemic Stroke / 
TIA 
I630 Cerebral infarct due to thrombosis of precerebral arteries 
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Ischemic Stroke / 
TIA 
I634 Cerebral infarction due to embolism of cerebral arteries 
Ischemic Stroke / 
TIA 
I631 Cerebral infarction due to embolism of precerebral arteries 
Ischemic Stroke / 
TIA 
I633 Cerebral infarction due to thrombosis of cerebral arteries 
Ischemic Stroke / 
TIA 
I639 Cerebral infarction unspecified 
Ischemic Stroke / 
TIA 
I635 Cerebral infarct due unspecified occlusion or stenos cerebral arts 
Ischemic Stroke / 
TIA 
I638 Other cerebral infarction 
Ischemic Stroke / 
TIA 
I693 Sequelae of cerebral infarction 
Ischemic Stroke / 
TIA 
I694 Sequelae of stroke not specified as hemorrhage or infarction 
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Table S3. OPCS codes (versions 4.5 to 4.8) for major adverse outcomes. 
Procedure Code Description 
CABG K401 Saphenous vein graft replacement of one coronary artery 
CABG K402 Saphenous vein graft replacement of two coronary arteries 
CABG K403 Saphenous vein graft replacement of three coronary arteries 
CABG K404 Saphenous vein graft replacement of four or more coronary 
arteries 
CABG K408 Other specified saphenous vein graft replacement of coronary 
artery 
CABG K409 Unspecified saphenous vein  graft replacement of coronary 
artery 
CABG K411 Autograft replacement of one coronary artery 
CABG K412 Autograft replacement of two coronary arteries 
CABG K413 Autograft replacement of three coronary arteries 
CABG K414 Autograft replacement of four or more coronary arteries 
CABG K418 Other specified other autograft replacement of coronary artery 
CABG K419 Unspecified other autograft replacement of coronary artery 
CABG K421 Allograft replacement of one coronary artery 
CABG K422 Allograft replacement of two coronary arteries 
CABG K423 Allograft replacement of three coronary arteries 
CABG K424 Allograft replacement of four coronary arteries 
CABG K428 Other specified allograft replacement of coronary artery 
CABG K431 Prosthetic replacement of one coronary artery 
CABG K442 Revision of replacement of coronary artery 
CABG K451 Double anastomosis of mammary arteries to coronary arteries 
CABG K453 Anastomosis of mammary artery to left anterior descending 
coronary artery 
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CABG K454 Anastomosis of mammary artery to coronary artery NEC 
CABG K471 Endarterectomy of coronary artery 
Coronary PCI K49 Transluminal balloon angioplasty of coronary artery 
Coronary PCI K491 Percutaneous transluminal balloon angioplasty of one coronary 
artery 
Coronary PCI K492 Percutaneous transluminal balloon angioplasty of multiple 
coronary arteries 
Coronary PCI K493 Percutaneous transluminal balloon angioplasty of bypass graft 
of coronary artery 
Coronary PCI K494 Percutaneous transluminal cutting balloon angioplasty of 
coronary artery 
Coronary PCI K498 Other specified transluminal balloon angioplasty of coronary 
artery 
Coronary PCI K499 Unspecified transluminal balloon angioplasty of coronary artery 
Coronary PCI K503 Percutaneous transluminal injection of therapeutic substance 
into coronary artery 
Coronary PCI K504 Percutaneous transluminal atherectomy of coronary artery 
Coronary PCI K75 Percutaneous transluminal balloon angioplasty and insertion of 
stent into coronary artery 
Coronary PCI K751 Percutaneous transluminal balloon angioplasty and insertion of 
1-2 drug-eluting stents into coronary artery 
Coronary PCI K752 Percutaneous transluminal balloon angioplasty and insertion of 
3 or more drug-eluting stents into coronary artery 
Coronary PCI K753 Percutaneous transluminal balloon angioplasty and insertion of 
1-2 stents into coronary artery 
Coronary PCI K754 Percutaneous transluminal balloon angioplasty and insertion of 
3 or more stents into coronary artery NEC 
Coronary PCI K758 Other specified percutaneous transluminal balloon angioplasty 
and insertion of stent into coronary artery 
Coronary PCI K759 Unspecified percutaneous transluminal balloon angioplasty and 
insertion of stent into coronary artery 
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Coronary PCI Y141 Insertion of expanding covered metal stent into organ NOC 
Coronary PCI Y142 Insertion of expanding metal stent into organ NOC 
Coronary PCI Y143 Insertion of metal stent into organ NOC 
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 Table S4. Demographics and medical history of patients included and excluded in the 
analysis*  
N=3,459 
 Included Excluded P 
 
Percentage of overall  
n=2,090 
60.4 
N = 1,369 
39.6 
 
Mean age, (SD) 63.2 (11.8) 65.9 (12.2) <0.001 
Characteristic, n (%)    
     Male 1537 (73.5) 942 (68.8) 0.003 
    Obese 511 (24.4) 345 (25.2) 0.62 
    Smoker 784 (37.5) 496 (36.2) 0.45 
Deprivation index   0.12 
    1 337 (16.4) 250 (18.2)  
    2 411 (20.0) 260 (18.9)  
    3 489 (23.9) 337 (24.6)  
    4 415 (20.2) 229 (16.7)  
    5 398 (19.4) 264 (19.3)  
     Unknown 40 (1.9) 29 (2.1)  
Prior medical history, n(%)    
    Hypertension 851 (40.7) 608 (44.4) 0.03 
    Ischemic Heart Disease 612 (29.3) 525 (38.3) <0.001 
    Myocardial Infarction 351 (16.8) 280 (20.5) 0.006 
    Coronary revascularization 203 (9.7) 209 (15.3) <0.001 
    Ischemic Stroke 115 (5.5) 97 (7.1) 0.06 
D
ow
nloaded from
 http://ahajournals.org by on November 21, 2019
   
    Heart Failure 259 (12.4) 237 (17.3) <0.001 
    Vascular Disease 81 (3.9) 81 (5.9) <0.001 
    Thromboembolism 14(0.7) 17 (0.7) 0.36 
    Diabetes 382 (18.3) 297 (21.7) 0.01 
    CKD Stage 4+ 16 (0.8) 16 (1.2) 0.22 
    Chronic liver Disease 24 (1.1) 13 (0.9) 0.58 
    Dyslipidemia 380 (18.2) 288 (21.0) 0.04 
    Dementia 9 (0.4) 9 (0.7) 0.36 
    Prior bleeding events  205 (9.8) 164 (12.0) 0.04 
 
    Aspirin 711 (34.0) 610 (44.6) <0.001 
    P2Y12 antagonist 230 (11.0) 265 (19.6) <0.001 
    Statins 924 (44.2) 733 (53.5) <0.001 
Clinical syndrome, n (%)   <0.001 
    ACS 1808 (86.5) 1030 (75.2)  
    Stable 282 (13.5) 339 (24.8)  
*Comparisons made here are between those meeting the inclusion criteria and prescribed 
clopidogrel for one year (n=2090) and those not meeting the inclusion criteria but had linked 
data available before the index admission, survived at least one day after discharge but did not 
have AF or received CABG during the index admission. Comparisons are made using the 2 test 
for categorical variables and the independent T test for continuous variables 
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Table S5. Multivariable Cox proportional hazard model of characteristics associated with 
the independent adverse outcomes of MI, ischemic stroke, coronary revascularization or 
death. 
 
INDIVIDUAL OUTCOMES OF MI, ISCHEMIC STROKE, CORONARY REVASCULARIZATION AND 
DEATH 
The primary outcome measure (the composite of MI, ischemic stroke, coronary revascularization 30 days’ post 
discharge and death) occurred in 286 (13.7%) of the cohort. The number of patients having an MI during follow 
up was 167 (8.0%), ischemic stroke 31 (1.5%), coronary revascularization 100 (4.8%) and death 46 (2.2%). For 
completeness we modelled baseline characteristics and the time dependent effects of discontinuation and /or 
bleeding against these individual outcome measures in a multivariable Cox-proportional hazard model (table S5). 
In these models we found no significant association between discontinuation and/or bleeding on coronary 
revascularization. We also calculated the event rate per 100 patient years (table S6). In the case of MI, 
revascularization and stroke there were no patients who had both clopidogrel discontinuation and bleeding events 
prior to the adverse outcome. 
 
 Adverse outcome 
 MI Ischemic Stroke Revascularization Death 
 HR (95% CI), p 
value 
HR (95% CI), p value HR (95% CI), p 
value 
HR (95% CI), p 
value 
Covariate  - - - 
Age decile  - - - 
     ≤49 2.44 (1.42-4.2), - - - 
    50- 59 Reference, p=0.21 - - - 
    60-69 1.71 (1.05-2.78) - - - 
    70-79 1.96 (1.19-3.22) - - - 
    ≥80 1.99 (1.08-3.67) - - - 
Hypertension - 2.29 (1.06-4.97), 
p=0.035 
- - 
Liver disease 2.74 (1.21-6.22), 
p=0.016 
- - - 
CKD stage 4+ - - 6.43 (2.35-17.45), 
<0.001 
- 
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Previous 
revascularization 
2.42 (1.64-3.59), 
p<0.001 
- 1.83 (1.09-3.07), 
p=0.02 
- 
Previous ischemic 
stroke 
- 5.71 (2.58-12.66), 
P<0.001 
2.21 (1.19-4.09), 
p=0.01 
- 
Previous 
thromboembolism 
- - 3.33 (1.03-10.73), 
p=0.04 
- 
Heart failure - 4.03 (1.95-8.30), 
P<0.001 
- - 
Clinical Syndrome 
    Stable CAD 
    ACS 
 
Reference 
2.09 (1.20-3.66), 
p=0.009 
- - - 
Previous 
Thromboembolism 
4.68 (2.15-10.19), 
P<0.001 
- - - 
Time dependent variable of discontinuation and/or bleed                         
     No discontinuation 
and no bleed 
Reference, p<0.001 Reference, p<0.001 - Reference, p<0.001 
     (1) Discontinuation 
only 
1.76 (0.76-4.05) - - 6.00 (2.44-14.76) 
     (2) Bleed only 5.78 (2.88-11.60) 9.78 (3.30-28.95) - 5.94 (1.79-19.72) 
(3) Discontinuation 
and         bleed 
- - - 61.47 (21.18-
178.39) 
*The following variables were included in the model: age; gender; presenting clinical syndrome; hypertension; prior 
coronary revascularization; prior bleeding events; ischemic stroke; heart failure; vascular disease; thromboembolism; 
diabetes; CKD stage 4+; chronic liver disease, dyslipidemia; dementia and time dependent variables or clopidogrel 
discontinuation, bleeding and both discontinuation and bleeding. Only variables associated with one or more outcomes 
are presented.  The final variables were selected in a multivariable co model by minimizing the Akaike information 
criterion. 
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Table S6. Individual event rate* for Stroke, MI, coronary revascularization and death according to 
presence of clopidogrel discontinuation and/or bleed. 
 
 MI Ischemic stroke Coronary 
revascularization 
Death 
No discontinuation and no 
bleed 
5.34 0.08 3.02 1.22 
Discontinuation only 17.43 0.07 12.43 6.06 
Bleed only 18.75 10.5 8.38 6.06 
Discontinuation and bleed - - - 64.6 
*Event rate calculated in events per 100 patient years. 
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Table S7. Multivariable Cox proportional hazard model of characteristics associated with bleeding events 
during follow up. 
 
Covariate HR CI lower CI upper p 
Prior bleeding 2.82 1.67 4.76 <0.001 
CKD stage 4+ 6.15 2.22 17.08 <0.001 
Chronic liver disease 3.62 1.14 11.51 <0.001 
*The following variables were included in the model: age; gender; presenting clinical syndrome; 
hypertension; prior coronary revascularization; prior bleeding events; ischemic stroke; heart failure; vascular 
disease; thromboembolism; diabetes; CKD stage 4+; chronic liver disease and dyslipidemia.  
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